HEALTH● LOWAug 6 · Aug 6, 2026, 10:45 PM
Immunocore outlines TEBE-AM data as early as end of 2026 while scaling KIMMTRAK beyond ~1,000 patients per year
Seeking Alpha Tech
Immunocore plans to release data for TEBE-AM by late 2026 and expand its KIMMTRAK treatment to over 1,000 patients annually. This highlights the company's progress in clinical development and patient reach for its therapies.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Health
HEALTH31m agoNMC withdraws 2023 rules on medical education standards, raising accountability concernsThe HinduHEALTH42m agoAmerica’s next great addiction crisisThe HillHEALTH1h agoBack pain: Lancet review calls for clinical assessment over routine scansThe HinduHEALTH1h agoFirst personalized cancer vaccine: reduction in disease recurrence risk in a major clinical trialBBC Afrique